Exploring the fatty acid amide hydrolase and cyclooxygenase inhibitory properties of novel amide derivatives of ibuprofen.
Amides
/ chemical synthesis
Amidohydrolases
/ antagonists & inhibitors
Animals
Cyclooxygenase 1
/ metabolism
Cyclooxygenase 2
/ metabolism
Dose-Response Relationship, Drug
Enzyme Inhibitors
/ chemical synthesis
Humans
Ibuprofen
/ chemical synthesis
Molecular Docking Simulation
Molecular Structure
Rats
Rats, Sprague-Dawley
Rats, Wistar
Structure-Activity Relationship
FAAH inhibition
Ibuprofen amides
cyclooxygenase
endocannabinoid
fatty acid amide hydrolase
Journal
Journal of enzyme inhibition and medicinal chemistry
ISSN: 1475-6374
Titre abrégé: J Enzyme Inhib Med Chem
Pays: England
ID NLM: 101150203
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
entrez:
24
3
2020
pubmed:
24
3
2020
medline:
28
10
2020
Statut:
ppublish
Résumé
Inhibition of fatty acid amide hydrolase (FAAH) reduces the gastrointestinal damage produced by non-steroidal anti-inflammatory agents such as sulindac and indomethacin in experimental animals, suggesting that a dual-action FAAH-cyclooxygenase (COX) inhibitor could have useful therapeutic properties. Here, we have investigated 12 novel amide analogues of ibuprofen as potential dual-action FAAH/COX inhibitors.
Identifiants
pubmed: 32200655
doi: 10.1080/14756366.2020.1743283
pmc: PMC7144264
doi:
Substances chimiques
Amides
0
Enzyme Inhibitors
0
Cyclooxygenase 1
EC 1.14.99.1
Cyclooxygenase 2
EC 1.14.99.1
Amidohydrolases
EC 3.5.-
fatty-acid amide hydrolase
EC 3.5.1.-
Ibuprofen
WK2XYI10QM
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
815-823Références
Eur J Pharmacol. 2017 Jul 15;807:198-204
pubmed: 28478068
Eur J Med Chem. 2010 Sep;45(9):3564-74
pubmed: 20570023
Trends Pharmacol Sci. 2014 Jul;35(7):358-67
pubmed: 24845457
J Comput Aided Mol Des. 2013 Mar;27(3):221-34
pubmed: 23579614
ACS Med Chem Lett. 2012 Sep 13;3(9):759-763
pubmed: 22984634
Eur J Med Chem. 2017 Aug 18;136:523-542
pubmed: 28535469
PLoS One. 2014 Jul 25;9(7):e103589
pubmed: 25061885
Science. 2002 Nov 29;298(5599):1793-6
pubmed: 12459591
Am J Med. 1998 Mar 30;104(3A):23S-29S; discussion 41S-42S
pubmed: 9572317
J Pharmacol Exp Ther. 2011 Sep;338(3):795-802
pubmed: 21659471
Pharmacol Res. 2012 May;65(5):553-63
pubmed: 22420940
J Biochem Biophys Methods. 2004 Aug 31;60(2):171-7
pubmed: 15262451
Eur J Pharmacol. 2007 Jun 22;565(1-3):26-36
pubmed: 17397826
Eur J Med Chem. 2003 May;38(5):513-8
pubmed: 12767601
Bioorg Med Chem Lett. 2011 Apr 15;21(8):2492-6
pubmed: 21392988
J Enzyme Inhib Med Chem. 2013 Feb;28(1):172-82
pubmed: 22225576
J Med Chem. 2004 Mar 25;47(7):1739-49
pubmed: 15027865
Expert Opin Ther Pat. 2015;25(11):1247-66
pubmed: 26413912
J Biol Chem. 2018 Mar 2;293(9):3028-3038
pubmed: 29326169
FASEB J. 2015 Jun;29(6):2616-27
pubmed: 25757568
J Pharmacol Exp Ther. 2009 Apr;329(1):48-56
pubmed: 19118134
J Enzyme Inhib Med Chem. 2019 Dec;34(1):562-576
pubmed: 30688118
Eur J Med Chem. 2015 Feb 16;91:15-26
pubmed: 25240419
Nat Chem Biol. 2011 Nov;7(11):803-9
pubmed: 22053353
PLoS One. 2015 Nov 13;10(11):e0142711
pubmed: 26565710
Eur J Med Chem. 2016 Feb 15;109:216-37
pubmed: 26774927
J Med Chem. 2012 Oct 25;55(20):8807-26
pubmed: 23043222
J Comput Chem. 2005 Dec;26(16):1752-80
pubmed: 16211539
J Comput Aided Mol Des. 2007 Dec;21(12):681-91
pubmed: 17899391
Biochem Pharmacol. 1993 Sep 1;46(5):791-6
pubmed: 8373432
J Pharmacol Exp Ther. 1997 Nov;283(2):729-34
pubmed: 9353392
J Biol Chem. 1993 Mar 25;268(9):6610-4
pubmed: 8454631
J Med Chem. 2004 Mar 25;47(7):1750-9
pubmed: 15027866